Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: Tel Aviv
  • Sector: Financials
  • Industry: Asset Management
  • Sub-Industry: Investment Companies

Bio Light Israeli Life Sciences Investments Ltd

+ Add to Watchlist


17.50 ILs 0.30 1.74%

As of 10:24:17 ET on 03/02/2015.

Snapshot for Bio Light Israeli Life Sciences Investments Ltd (BOLT)

Open: 17.20 Day's Range: 17.20 - 17.70 Volume: 967,324
Previous Close: 17.20 52wk Range: 13.10 - 23.20 1-Yr Rtn: -15.05%

Stock Chart for BOLT

No chart data available.
  • BOLT:IT 17.40
  • 1D
  • 1M
  • 1Y
Interactive BOLT Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BOLT

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. TA-100 -
Earnings Per Share (ttm) -0.0610
Est. EPS -
Est. PEG Ratio -
Market Cap (M ILS) 91.23
Shares Outstanding (M) 521.34
30 Day Average Volume 1,182,990
Price/Book (mrq) 2.7658
Price/Sale (ttm) 373.1801
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/31/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BOLT

  • Revenue
  • Net Income (M/ILS)
  • Profit Margin (%)

Company Profile & Key Executives for BOLT

Bio Light Israeli Life Sciences Investments Ltd. is a holding company. The Company through subsidiary companies develops a drug for weight management, and another drug for blocking allergies. The Company developed laser based non-invasive technology for the treatment of Glaucoma, and is developing diagnostic kits for surgical cancer procedures and cancer drugs.

Suzana Nahum ZilberbergChief Executive OfficerItai Bar-NatanChief Financial Officer
More Company Profile & Key Executives for BOLT

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil